emerge.png
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
16. Dezember 2024 08:00 ET | Emergent BioSolutions
GAITHERSBURG, Md., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the...
HOPOlogo_small.png
HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity
28. Oktober 2024 10:00 ET | HOPO Therapeutics, Inc.
HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity
Crossject annonce de
Crossject annonce des progrès majeurs dans la fabrication de son traitement d’urgence ZEPIZURE®, pour la prise en charge des crises d’épilepsie, à l’approche du dépôt d’une demande d’autorisation d’utilisation d’urgence aux États-Unis.
22. Oktober 2024 01:30 ET | CROSSJECT
Le lot de produits annoncé en juillet a permis de recueillir davantage de données de stabilité, qui au premier trimestre 2025 soutiendront directement la stabilité requise de six  mois.Crossject...
Crossject reports st
Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE® ahead of filing U.S. Emergency Use Authorization
22. Oktober 2024 01:30 ET | CROSSJECT
Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025Crossject expects to file...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
22. Oktober 2024 00:30 ET | BioAegis Therapeutics
Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
17. Oktober 2024 08:07 ET | BioAegis Therapeutics
Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC
12. September 2024 16:56 ET | BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that its...
emerge.png
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
12. September 2024 08:30 ET | Emergent BioSolutions
GAITHERSBURG, Md., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a contract modification executing an option period by the Biomedical...
Crossject franchit u
Crossject franchit une nouvelle étape clé dans la fabrication de ZEPIZURE®
18. Juli 2024 01:30 ET | CROSSJECT
Fabrication réussie d’un autre Lot Règlementaire de ZEPIZURE® sur le nouveau site de fabricationUne étape importante qui complète les résultats satisfaisants obtenus avec les lots précédents dans le...
Crossject achieves k
Crossject achieves key ZEPIZURE® manufacturing milestone
18. Juli 2024 01:30 ET | CROSSJECT
Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing siteMilestone complements the satisfying results from previous batches under stability studies, and is...